Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed Phase 2 Interventional Results available

High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

NCT00735969
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Peginterferon, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

NCT01590654
View directory record Official record
Conditions
Hepatitis B
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

NCT04676724
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, PegIFN, NA therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Sacramento, California • Iowa City, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

Study of Hepatitis C Treatment During Pregnancy

NCT02683005
View directory record Official record
Conditions
Hepatitis C, Pregnancy
Interventions
ledipasvir/sofosbuvir
Drug
Lead sponsor
Catherine Chappell
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

NCT01858766
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
50
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

NCT01482403
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

Ph IIA Study (SOC +/- NS5B)

NCT01193361
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 25, 2026, 8:16 AM EDT
Not listed No phase listed Observational

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Not applicable Interventional

Community Access, Retention in Care, and Engagement for Hepatitis C Treatment

NCT03581383
View directory record Official record
Conditions
Hepatitis C
Interventions
PREP-C, Modified ECHO, Patient Telemedicine Questionnaire
Behavioral
Lead sponsor
Jens Rosenau
Other
Eligibility
18 Years to 99 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention

NCT03706742
View directory record Official record
Conditions
Hepatitis C, HepatoCellular Carcinoma
Interventions
Mailed outreach
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
53 Years to 74 Years
Enrollment
12,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 25, 2026, 8:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2Phase 3 Interventional

Study to Reduce Intravenous Exposures (STRIVE)

NCT00391482
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peer Mentoring Intervention for HCV-Infected IDUs
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 35 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

NCT00874796
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SCOPE-Chinese Women Study

NCT04326660
View directory record Official record
Conditions
Cancer, Breast, Obesity, Abdominal
Interventions
SCOPE-Chinese Women
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

NCT01368497
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir and peginterferon
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 4 Interventional Results available

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

NCT00371150
View directory record Official record
Conditions
Hepatitis B Infection
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
14
States / cities
Montgomery, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

NCT03501550
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
CDI-31244, SOF/VEL
Drug
Lead sponsor
Cocrystal Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 1Phase 2 Interventional

Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

NCT00771446
View directory record Official record
Conditions
Acute Hepatitis, Chronic Hepatitis
Interventions
ELAD plus standard of care treatment, Standard of care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
19 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

NCT03214679
View directory record Official record
Conditions
Hepatitis C, People Who Inject Drugs, PWID, HCV Coinfection
Interventions
Accessible Care, Usual Care
Other
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Building on Needle Exchange to Optimize Prevention & Treatment

NCT03567174
View directory record Official record
Conditions
Intravenous Drug Usage, HIV/AIDS
Interventions
Integrated care van (ICV)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 3 Interventional Results available

Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone

NCT00376259
View directory record Official record
Conditions
Hepatitis B
Interventions
telbivudine, adefovir dipivoxil
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
San Diego, California • San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 25, 2026, 8:16 AM EDT
Recruiting No phase listed Observational

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

NCT00404989
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
12 Years to 60 Years · Female only
Enrollment
24,258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2099
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 8:16 AM EDT